The COVID-19 Registry Japan (COVIREGI-JP), a registry of patients hospitalized with coronavirus disease (COVID-19), contains the largest national COVID-19 inpatient population. Since COVIREGI- JP invites voluntary participation by facilities, selection bias is inevitable. The current study examined the representativeness of COVIREGI-JP data in comparison to open-source national data. The number of infections and deaths among hospitalized COVID-19 patients in COVIREGI-JP were compared to those in national data recorded during the six waves of the COVID-19 epidemic until March 6, 2022. During the period studied, patients in COVIREGI-JP represented 1% of the total COVID-19 cases according to national data; the proportion was high during the first wave (32.7%) and tended to decrease, especially after the fourth wave. The overall proportion of patients from each region varied from 0.8% to 2.5%, but case fatality rates in COVIREGI-JP tended to be higher than those in the national data, with the exception of a few waves, in several regions. The difference was smallest during the first wave. Although COVIREGI-JP consistently registered cases from all regions of the country, the proportion tended to decline after the beginning of the epidemic. Given the epidemiological persistence and the ever-changing epidemiology of COVID-19, continued case registration and data utilization in COVIREGI-JP is desirable, although selection bias in COVIREGI-JP registration of cases should be carefully interpreted.
He was diagnosed with adhesive bowel obstruction, which was treated conservatively and the patient recovered
M/22
Tonsillitis
29
Serious
Related/cannot be ruled out
The subject with no previous medical history presented with mild sore throat and fever appearing on Day 6 post-vaccination, which was judged to have been caused by the vaccination by the site physician. No adverse event occurred to the baby
ht Onset time is counted from vaccination day (vaccination = Day 0). He was diagnosed with adhesive bowel obstruction, which was treated conservatively and the patient recovered
M/22
Tonsillitis
29
Serious
Related/cannot be ruled out
The subject with no previous medical history presented with mild sore throat and fever appearing on Day 6 post-vaccination, which was judged to have been caused by the vaccination by the site physician. On 24 July 2017, Sanofi Pasteur, yellow fever vaccine (YF-VAX) manufacturer, announced a vaccine shortage caused by manufacturing delays.[1] Consequently, some countries were forced to take compensatory measures. [Extracted from the article]
Background The aim of this study was to identify associations between smoking status and the severity of COVID-19, using a large-scale data registry of hospitalized COVID-19 patients in Japan (COVIREGI-JP), and to explore the reasons for the inconsistent results previously reported on this subject. Methods The analysis included 17 666 COVID-19 inpatients aged 20–89 years (10 250 men and 7416 women). We graded the severity of COVID-19 (grades 0 to 5) according to the most intensive treatment required during hospitalization. The smoking status of severe grades 3/4/5 (invasive mechanical ventilation/extracorporeal membrane oxygenation/death) and separately of grade 5 (death) were compared with that of grade 0 (no oxygen, reference group) using multiple logistic regression. Results were expressed as odds ratios (OR) and 95% confidence intervals (CI) adjusted for age and other factors considering the potential intermediate effects of comorbidities. Results Among men, former smoking significantly increased the risk of grade 3/4/5 and grade 5, using grade 0 as a reference group, with age- and admission-date-adjusted ORs (95% CI) of 1.51 (1.18–1.93) and 1.65 (1.22–2.24), respectively. An additional adjustment for comorbidities weakened the ORs. Similar results were seen for women. Current smoking did not significantly increase the risk of grade 3/4/5 and grade 5 in either sex. Conclusions The severity of COVID-19 was not associated with current or former smoking per se but with the comorbidities caused by smoking. Thus, smoking cessation is likely to be a key factor for preventing smoking-related disease and hence for reducing the risk of severe COVID-19. [ABSTRACT FROM AUTHOR]